GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Asset Turnover
中文

Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Asset Turnover

: 0.12 (As of Dec. 2023)
View and export this data going back to 1952. Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Bristol-Myers Squibb Co's Revenue for the three months ended in Dec. 2023 was $11,477 Mil. Bristol-Myers Squibb Co's Total Assets for the quarter that ended in Dec. 2023 was $93,211 Mil. Therefore, Bristol-Myers Squibb Co's Asset Turnover for the quarter that ended in Dec. 2023 was 0.12.

Asset Turnover is linked to ROE % through Du Pont Formula. Bristol-Myers Squibb Co's annualized ROE % for the quarter that ended in Dec. 2023 was 24.13%. It is also linked to ROA % through Du Pont Formula. Bristol-Myers Squibb Co's annualized ROA % for the quarter that ended in Dec. 2023 was 7.56%.


Bristol-Myers Squibb Co Asset Turnover Historical Data

The historical data trend for Bristol-Myers Squibb Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.34 0.41 0.45 0.47

Bristol-Myers Squibb Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.12 0.12 0.12

Competitive Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co Asset Turnover Distribution

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Asset Turnover falls into.



Bristol-Myers Squibb Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Bristol-Myers Squibb Co's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=45006/( (96820+95159)/ 2 )
=45006/95989.5
=0.47

Bristol-Myers Squibb Co's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=11477/( (91263+95159)/ 2 )
=11477/93211
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Bristol-Myers Squibb Co  (NYSE:BMY) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Bristol-Myers Squibb Co's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=7048/29214
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(7048 / 45908)*(45908 / 93211)*(93211/ 29214)
=Net Margin %*Asset Turnover*Equity Multiplier
=15.35 %*0.4925*3.1906
=ROA %*Equity Multiplier
=7.56 %*3.1906
=24.13 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Bristol-Myers Squibb Co's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=7048/93211
=(Net Income / Revenue)*(Revenue / Total Assets)
=(7048 / 45908)*(45908 / 93211)
=Net Margin %*Asset Turnover
=15.35 %*0.4925
=7.56 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Bristol-Myers Squibb Co Asset Turnover Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Business Description

Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Executives
Christopher S. Boerner officer: EVP, Chief Commercial Officer 21823 30TH DRIVE S, BOTHELL WA 98021
Samuels Theodore R. Ii director 1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge officer: SVP, Human Resources BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge officer: EVP, Chief Research Officer C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky officer: EVP, Chief Commercial Officer BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio officer: EVP & Chief Commercial Officer BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt director BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung officer: Vice President and Secretary C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees officer: SVP & Controller BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Autenried Paul Von officer: SVP, Enterp. Services & CIO BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543